Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Sagimet Biosciences Inc.NASDAQ: SGMT
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 6.3% from a year ago
Other current liabilities stood at $15K at the end of Q1 FY2026, down 6.3% from a year earlier and down 44.4% from the prior quarter. Over 3 fiscal years it compounded at -22.0% a year.
Context
- Other current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -6.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 27K USD
- Year-over-year change
- +440.0%
- 4-year CAGR
- -38.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27K | +440.0% |
| FY2024 | 2024-12-31 | 5K | -99.1% |
| FY2023 | 2023-12-31 | 556K | +875.4% |
| FY2022 | 2022-12-31 | 57K | -69.2% |
| FY2021 | 2021-12-31 | 185K | — |
Other Current Liabilities vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 other current liabilities of $15K is the 10th highest of the 11 companies compared; the peer median is $3.77M.
- Its year-over-year change of -6.3% is the 8th highest of 10, against a peer median of +44.2%.
- Other current liabilities amounts to 0.0% of total assets for SGMT, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.11B | +304928.8% | +7.5% | 1.4% | |
| Mar 2026 | $23.29M | — | +31.3% | 8.7% | |
| Mar 2026 | $5.49M | -13.6% | +19.8% | 2.2% | |
| Mar 2026 | $5.41M | +170.2% | +7.7% | 2.4% | |
| Mar 2026 | $4.24M | -0.0% | +18.8% | 1.3% | |
| Mar 2026 | $3.31M | +44.2% | +25.9% | 1.5% | |
| Mar 2026 | $2.37M | +29.6% | +132.4% | 1.0% | |
| Mar 2026 | $2.18M | +126.3% | +14.7% | 6.6% | |
ZURAZura Bio Limited | Mar 2026 | $1.13M | +57.7% | +6.1% | 0.5% |
SGMTSagimet Biosciences Inc. | Mar 2026 | $15K | -6.3% | -22.0% | 0.0% |
| Mar 2026 | $0 | -100.0% | +16.2% | 0.0% | |
| Peer median (excluding SGMT) | $3.77M | +44.2% | +17.5% | 1.5% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.